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Abstract
Background: We report a large family with four successive generations, presenting with a complex phenotype of
severe congenital neutropenia (SCN), partially penetrant monocytosis, and hearing loss of varying severity.
Methods: We performed whole exome sequencing to identify the causative variants. Sanger sequencing was used
to perform segregation analyses on remaining family members.
Results: We identified and classified a pathogenic GFI1 variant and a likely pathogenic variant in MYO6 which
together explain the complex phenotypes seen in this family.
Conclusions: We present a case illustrating the benefits of a broad screening approach that allows identification of
oligogenic determinants of complex human phenotypes which may have been missed if the screening was limited
to a targeted gene panel with the assumption of a syndromic disorder. This is important for correct genetic
diagnosis of families and disentangling the range and severity of phenotypes associated with high impact variants.
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Background
Severe congenital neutropenia (SCN) was first described
by Kostmann in 1956 in 14 individuals from 9 consan-
guineous families [1]. It is usually diagnosed in early
childhood and is characterized by chronic neutropenia,
susceptibility to bacterial infections and associated with
a predisposition to myelodysplastic syndrome (MDS) or
acute myeloid leukemia (AML). SCN is genetically hetero-
geneous with autosomal recessive, autosomal dominant
(AD) and X-linked forms described as well as de novo
cases [2]. It may also occur as a part of a syndrome with
other developmental defects (e.g. Shwachman-Diamond
Syndrome) [3]. We describe a family with a complex
phenotype of SCN and hearing loss of varying severity.
The genetic basis of SCN is well described and involves
mutations in a number of different genes (Supplemental
Table S2). Pathogenic variants in ELANE, the gene encod-
ing neutrophil elastase, are the most common cause of
AD SCN. Growth factor independent 1 transcriptional re-
pressor (GFI1) germline variants have been reported in
four patients with neutropenia; inheritance patterns were
consistent with an AD mode of inheritance [4]. HAX1 var-
iants underlie some autosomal recessive forms and were
found to be the underlying cause of SCN in the families
originally described by Kostmann [5]. It has been sug-
gested that these variants impair neutrophil maturation
via defective CSF3R signaling as the number of G-CSF re-
ceptors on myeloid precursors of SCN patients is elevated
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and majority of SCN patients benefit from the administra-
tion of pharmacological doses of granulocyte colony
stimulating factor (G-CSF) [6].
Depending on the causative genetic lesion, neutro-
penia can sometimes present with extra-haematopoietic
abnormalities such as pancreatic exocrine insufficiency
(SBDS, ELF1) and deafness (GATA2). We previously re-
ported heritable variants in GATA2 as predisposing to
familial MDS and AML [7]. Since then, a high incidence
of GATA2 variants has been found in patients with mild
neutropenia who evolve to develop MDS and AML [8].
Interestingly, sensorineural hearing loss and monocyto-
penia are other manifestations associated with haploin-
sufficiency of GATA2. Here, we report a large family




Blood and hair samples were obtained with consent
from members of the family as part of the Australia
Familial Haematological Cancer Study (AFHCS). gDNA
was isolated using the QIAamp DNA Mini Kit (Qiagen).
Whole exome sequencing (WES)
We performed WES (SeqCap EZ MedExome, Roche
NimbleGen) on two individuals (III-1 proband and IV-
1). Variant annotation was performed through our
ACRF Cancer Genomics Facility custom pipeline, which
takes into consideration pathogenicity/oncogenicity pre-
dictions (CADD> 10, Polyphen 2, SIFT, Mutation Taster,
GERP > 2, COSMIC parameters including specific-
mutation and gene frequency), population minor allele
frequencies (1000 GP, ESP, gnomAD), OMIM, and Gene
Ontology. All candidate variants were manually curated
to remove errors. The variants were interrogated for
known SCN genes (Table S2) and non-syndromic hear-
ing loss (Table S3).
Sanger sequencing
Sanger sequencing was performed on available samples
for confirmation of GFI1 and MYO6 variants in family
members to perform segregation analysis.
Results
We identified a five-generation kindred with four succes-
sive generations affected by congenital neutropenia (10 in-
dividuals; eight also had monocytosis – available blood
counts in Table S1) and five generations affected by hear-
ing loss of varying severity (13 individuals) (Fig. 1a,
Table 1). Sanger sequencing of GATA2 was performed
due to partial overlap in the phenotypes observed within
the family, but no pathogenic coding variants were found.
We therefore performed whole exome sequencing on III-
Fig. 1 Family with inherited neutropaenia, monocytosis and hearing impairment associated with mutations in GFI1 and MYO6. Pedigree,
phenotypes and mutation status are indicated as per the key provided (a). Causative heterozygous mutations in GFI1 (p.N382S/c.1145A > G) and
MYO6 (p.I1176L/c.3526A > C) were identified by whole exome sequencing performed on III-1 and IV-1. Sanger sequencing on available samples
from consenting individuals was used for segregation analysis and confirmation of variants in individuals denoted by ‘+’ and ‘#’, respectively (b)
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1 and IV-1(see Methods). The variants were interrogated
for known SCN genes (Supplemental Table S2). We iden-
tified a previously reported variant underlying congenital
neutropenia in GFI1 (NM_005263.5, c.1145A >G/
p.Asn382Ser, N382S) (Fig. 1b, left panel) [4]. The N382S
variant segregated with neutropenia in 6 consenting family
members who were tested (Table 1) including V-5 who re-
ported having had low white cells counts (blood reports
unavailable). With the addition of these 6 cases to the 3
previously reported individuals, this variant can now be
classified as a pathogenic variant, as per ACMG variant
classification guidelines (Supplemental Table S4) [9].
As GFI1 variants have not previously been associated
with hearing loss, we explored additional genetic causes
for the hearing loss phenotype observed in this family.
Over 100 genes have been reported to underlie heredi-
tary hearing loss. Analysis of the data for variants in
genes associated with non-syndromic hearing loss
(Supplemental Table S3), identified a novel single nu-
cleotide variant in MYO6 (NM_004999.4, c.3526A > C/
p.Ile1176Leu, I1176L) (Fig. 1b, right panel), a gene that
has previously been associated with AD hearing loss
[10]. The novel MYO6 I1176L variant segregated with
hearing loss in all but one individual (V-5) who dis-
played clinically unconfirmed mild hearing loss (Fig. 1a).
Supplemental Table S4 summarizes variant annotation
and classification.
Discussion
Congenital neutropenia and monocytosis due to GFI1
variants was first reported in 2003, following the obser-
vation that GFI1-deficient mice were unexpectedly neu-
tropenic [4]. GFI1 encodes a zinc finger transcriptional
repressor oncoprotein. The N382S variant occurs in a
highly evolutionarily conserved region of the GFI1 pro-
tein (Supplemental Figure S1). In vitro studies demon-
strated that the variant acted in a dominant negative
manner, abolishing DNA binding and hence repressor
activity of the protein [4]. Interestingly, GFI1 recruits to
chromatin the enzyme lysine-specific demethylase-1
(LSD1); pharmacologic inhibition of LSD1 or genetic
knock-down of LSD1 skews granulocyte-monocyte pro-
genitor differentiation resulting in neutropenia and mono-
cytosis as seen in this family [10]. LSD1 is currently a
target for the treatment of AML (NCT02842827).
SCN can be a pre-leukemic syndrome with evolution
to leukemia recognized in patients with ELANE and
HAX1 variants, as well as X-linked neutropenia (WAS).
Patients with SCN reportedly have a 21% cumulative in-
cidence of myeloid malignancy after 10 years with the
Table 1 Genotypes and phenotypes of various members in the family
Individual GFI1 Blood MYO6 Hearing
III-1 N382S (het) Neutropenia, monocytosis I1176L (het) Impaired
III-3 WT Normal WT Normal
IV-1 N382S (het) Neutropenia, monocytosis I1176L (het) Impaired
IV-2 N382S (het) Neutropenia, monocytosis I1176L (het) Impaired
IV-3 N382S (het) Neutropenia I1176L (het) Impaired
V-1 N382S (het) Neutropenia, monocytosis WT Normal
V-2 WT Normal I1176L (het) Very slight hearing loss
V-5 N382S (het) Has had low white cell counta WT Slight hearing loss
I-1 Unknown Unknown Unknown Impaired
I-2 Unknown Unknown Unknown Impaired in later years
II-1 Unknown Neutropenia, monocytosis Unknown Impaired
III-2 Unknown Neutropenia, monocytosis Unknown Impaired
IV-4 Unknown Neutropenia Unknown Impaired
IV-5 Unknown Normal Unknown Normal
IV-6 Unknown Unknown Unknown Impaired
IV-7 Unknown Normal Unknown Normal
V-3 Unknown Normal Unknown Normal
V-4 Unknown Normal Unknown Normal
V-6 Unknown Has had low white cell counta Unknown Normal
V-7 Unknown Unknown Unknown Slight hearing loss
V-8 Unknown Unknown Unknown Normal
Abbreviations: WT Wildtype, het Heterozygous
areported in patient questionnaires/interview – no accompanying blood reports available
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risk of leukemia being higher in patients requiring high
doses of G-CSF, and is associated with acquired muta-
tions in CSF3R and RUNX1 [11].
To date, there have been no reports of MDS or AML
in individuals with GFI1 variants alone (3 with N382S, 1
with K403R, 1 with R412*) [4] with the exception of
three individuals who carried germline variants in both
GFI1 and ELANE [12]. Our family adds another 6 cases
of confirmed GFI1 variant carriers (aged 20–75 years)
and 2 likely carriers (over 71 years) without progression to
myeloid malignancy, suggesting that the GFI1 variant alone
does not confer a high risk of leukemia development.
Variants in myosin genes are known to be involved in
several types of syndromic and non-syndromic hearing
loss. Variants in myosin VI (MYO6) have been identified
in AD and recessive hearing loss [10, 13]. The primary
evidence for the association of myosin VI with the hear-
ing process is based on the Snell’s waltzer mice, that ex-
hibit deafness [14]. The myosin VI protein is highly
expressed at the base of stereocilia rootlets and in the
pericuticular necklace of the inner and outer hair cells of
the organ of Corti. MYO6 is required for the proper
maturation of inner hair cell ribbon synapses and it has
been shown to interact with DFNB9 (responsible for a
recessive form of deafness) via the globular domain [15].
The I1176L variant is surrounded by a block of con-
served amino acids and resides within a very highly con-
served region (Figure S1) showing 91% amino acid
sequence identity from p.Asn1165- Lys1285, that en-
codes the globular domain in the protein [15]. Miyagawa
et al. have reported various other variants within this
globular domain where the degree of hearing loss ranged
from mild to profound.
Intriguingly, GFI1 has also been reported to be essen-
tial for inner ear hair cell differentiation [15, 16]. Hence
individual V-5, who has reported slight hearing loss and
has tested wildtype for MYO6, but carries the GFI1 vari-
ant, is an interesting case in this respect. Another curi-
ous observation is that family members with severe
hearing impairment carry both variants while those
with milder hearing problems only carry either of the
variants. Though the MYO6 variant is most likely re-
sponsible for hearing loss in the family, it remains to
be established if the GFI1 variant contributes to the
phenotype.
Conclusions
We have presented a family with a complex phenotype
of SCN and hearing loss that can be attributed to AD
variants in two genes, GFI1 causing SCN, and MYO6
leading to hearing loss. Broader screening may be war-
ranted in cases with complex disease presentations as
polygenic inheritance could be missed if testing is re-
stricted to specific gene panels. Although progression to
leukemia has not been described to date in the limited
number of individuals carrying germline pathogenic
GFI1 variants, it remains to be established whether
molecular monitoring for acquired variants should be
considered as part of a risk management scheme.
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